A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

Do Youn Oh, Yongjun Cha, In Sil Choi, So Young Yoon, In Keun Choi, Jee Hyun Kim, Sang Cheul Oh, Chang Duck Kim, Jae Seon Kim, Yung Jue Bang, Yeul Hong Kim

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Methods: Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m2 was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m2 was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. Results: A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32% [95% confidence interval (CI) 17-48%]. The median response duration was 6.0 months (95% CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95% CI 2.9-8.0 months), and the median overall survival was 8.4 months (95% CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5%), leukopenia (15.8%), thrombocytopenia (2.6%), and anemia (7.9%). The major grade 3/4 non-hematologic toxicities included anorexia (10.5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Conclusions: Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer.

Original languageEnglish
Pages (from-to)527-536
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume65
Issue number3
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

gemcitabine
Chemotherapy
Combination Drug Therapy
Pancreatic Neoplasms
Toxicity
Confidence Intervals
Fatigue of materials
Stomatitis
Hyperbilirubinemia
Leukopenia
Anorexia
Exanthema
Neutropenia
Thrombocytopenia
Fatigue
S 1 (combination)
Anemia
Adenocarcinoma

Keywords

  • Gemcitabine
  • Palliative
  • Pancreatic cancer
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. / Oh, Do Youn; Cha, Yongjun; Choi, In Sil; Yoon, So Young; Choi, In Keun; Kim, Jee Hyun; Oh, Sang Cheul; Kim, Chang Duck; Kim, Jae Seon; Bang, Yung Jue; Kim, Yeul Hong.

In: Cancer Chemotherapy and Pharmacology, Vol. 65, No. 3, 01.02.2010, p. 527-536.

Research output: Contribution to journalArticle

Oh, Do Youn ; Cha, Yongjun ; Choi, In Sil ; Yoon, So Young ; Choi, In Keun ; Kim, Jee Hyun ; Oh, Sang Cheul ; Kim, Chang Duck ; Kim, Jae Seon ; Bang, Yung Jue ; Kim, Yeul Hong. / A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. In: Cancer Chemotherapy and Pharmacology. 2010 ; Vol. 65, No. 3. pp. 527-536.
@article{996051ffc58840b09e26b40d966c5b97,
title = "A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer",
abstract = "Purpose: To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Methods: Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m2 was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m2 was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. Results: A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32{\%} [95{\%} confidence interval (CI) 17-48{\%}]. The median response duration was 6.0 months (95{\%} CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95{\%} CI 2.9-8.0 months), and the median overall survival was 8.4 months (95{\%} CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5{\%}), leukopenia (15.8{\%}), thrombocytopenia (2.6{\%}), and anemia (7.9{\%}). The major grade 3/4 non-hematologic toxicities included anorexia (10.5{\%}), stomatitis (2.6{\%}), rash (7.9{\%}), fatigue (7.9{\%}) and hyperbilirubinemia (5.3{\%}). Conclusions: Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer.",
keywords = "Gemcitabine, Palliative, Pancreatic cancer, S-1",
author = "Oh, {Do Youn} and Yongjun Cha and Choi, {In Sil} and Yoon, {So Young} and Choi, {In Keun} and Kim, {Jee Hyun} and Oh, {Sang Cheul} and Kim, {Chang Duck} and Kim, {Jae Seon} and Bang, {Yung Jue} and Kim, {Yeul Hong}",
year = "2010",
month = "2",
day = "1",
doi = "10.1007/s00280-009-1059-9",
language = "English",
volume = "65",
pages = "527--536",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

AU - Oh, Do Youn

AU - Cha, Yongjun

AU - Choi, In Sil

AU - Yoon, So Young

AU - Choi, In Keun

AU - Kim, Jee Hyun

AU - Oh, Sang Cheul

AU - Kim, Chang Duck

AU - Kim, Jae Seon

AU - Bang, Yung Jue

AU - Kim, Yeul Hong

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Methods: Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m2 was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m2 was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. Results: A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32% [95% confidence interval (CI) 17-48%]. The median response duration was 6.0 months (95% CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95% CI 2.9-8.0 months), and the median overall survival was 8.4 months (95% CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5%), leukopenia (15.8%), thrombocytopenia (2.6%), and anemia (7.9%). The major grade 3/4 non-hematologic toxicities included anorexia (10.5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Conclusions: Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer.

AB - Purpose: To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Methods: Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m2 was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m2 was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. Results: A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32% [95% confidence interval (CI) 17-48%]. The median response duration was 6.0 months (95% CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95% CI 2.9-8.0 months), and the median overall survival was 8.4 months (95% CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5%), leukopenia (15.8%), thrombocytopenia (2.6%), and anemia (7.9%). The major grade 3/4 non-hematologic toxicities included anorexia (10.5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Conclusions: Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer.

KW - Gemcitabine

KW - Palliative

KW - Pancreatic cancer

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=75549083878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75549083878&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1059-9

DO - 10.1007/s00280-009-1059-9

M3 - Article

C2 - 19578850

AN - SCOPUS:75549083878

VL - 65

SP - 527

EP - 536

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -